Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 112

Results For "first"

3340 News Found

FDA approves Bayer’s Finerenone for new indication in patients with HF and LVEF of ?40%
Drug Approval | July 15, 2025

FDA approves Bayer’s Finerenone for new indication in patients with HF and LVEF of ?40%

Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,


Milestone Pharmaceuticals announces FDA acceptance of response to Cardamyst nasal spray CRL
Drug Approval | July 15, 2025

Milestone Pharmaceuticals announces FDA acceptance of response to Cardamyst nasal spray CRL

Milestone also announced the extension of its $75 million Royalty Purchase Agreement with RTW Investments


India launches nutraceutical trade expo ‘Bharat Nutraverse’
News | July 15, 2025

India launches nutraceutical trade expo ‘Bharat Nutraverse’

India’s nutraceutical industry is expected to reach over US$ 22 billion in 2025


Indegene launches NEXT Medical Writing Automation
News | July 12, 2025

Indegene launches NEXT Medical Writing Automation

To streamline complex medical writing workflows with GenAI


EU launches strategies to strengthen crisis readiness and health security
Policy | July 11, 2025

EU launches strategies to strengthen crisis readiness and health security

The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises


Merck to acquire Verona Pharma for US$ 10 billion
News | July 10, 2025

Merck to acquire Verona Pharma for US$ 10 billion

Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases


BioMed X and Servier launch AI-powered antibody research at New XSeed Labs in Paris-Saclay
News | July 09, 2025

BioMed X and Servier launch AI-powered antibody research at New XSeed Labs in Paris-Saclay

The first project will focus on developing an AI-based platform for the sterically guided design of bispecific antibodies


AB Science receives FDA and EMA authorization for phase 3 Trial of prostate cancer treatment
Clinical Trials | July 08, 2025

AB Science receives FDA and EMA authorization for phase 3 Trial of prostate cancer treatment

Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments


Everest Medicines progresses in AI-powered mRNA platform at 2025 R&D day
News | July 08, 2025

Everest Medicines progresses in AI-powered mRNA platform at 2025 R&D day

The company showcased three core programs developed through this platform